V-Wave Overview
V-Wave is focused on developing percutaneous implantable devices for treating patients with chronic heart failure. The companys vision is to help patients with disabling symptoms or who need hospitalization despite optimized medical treatment. V-Wave has developed the V-Wave Shunt, a miniature, biocompatible implant that regulates left atrial pressure (LAP), a primary cause of worsening symptoms that lead to over three million hospitalizations a year. The proprietary, unidirectional, interatrial shunt is designed to prevent episodes of elevated LAP, thereby improving symptoms, reducing hospitalizations, and increasing exercise tolerance and quality of life.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Johnson & Johnson buys Israeli co V-Wave for up to $1.1b
Johnson & Johnson has announced plans to acquire Israeli company V-Wave, a developer of heart failure treatments. The deal, worth an upfront payment of $600 million with potential for additional payments that could increase the total to $1.1 billion, is expected to close by the end of 2024. V-Waves product, the Ventura Interatrial Shunt, has already received marketing approval in Europe and is in the process of applying for FDA approval in the US. The company, which was founded in 2010, has previously raised funding from investors including Johnson & Johnson and Edwards.
AcquisitionInvestment
growth-positive
V-Wave Completes Enrollment in the RELIEVE-HF Randomized Double-Blind Controlled Trial of Interatrial Shunting for Heart Failure
V-Wave has completed enrollment in the RELIEVE-HF trial, a clinical trial assessing the safety and effectiveness of the V-Wave Ventura Interatrial Shunt for the treatment of heart failure. The trial enrolled 508 advanced heart failure patients and will analyze the results after 12 months of follow-up. The Ventura Shunt is an investigational device that aims to reduce hospitalizations and improve symptoms and quality of life for heart failure patients. The company has not reported any major adverse events related to the device. V-Wave is a privately held medical device company based in Israel and the U.S.
Customers
growth-positive
V-Wave's Ventura® Interatrial Shunt: One Year Follow-up from RELIEVE-HF Roll-in Arm Shows Improved Left and Right Ventricular Function in Patients with Advanced Heart Failure
V-Wave Ltd, the manufacturer of the V-Wave Ventura investigational interatrial shunt device, announced positive 12-month echocardiographic results from the RELIEVE-HF clinical trial. The trial showed improvement in cardiac function for patients with advanced heart failure. The patients who received the shunt during a minimally invasive procedure experienced no major adverse events. The findings suggest that the shunt device unloads high diastolic pressures in the left ventricle without overloading the right side of the heart. V-Wave plans to continue the trial and expects to complete enrollment by Fall 2022. The company aims to provide a definitive answer on the safety and effectiveness of interatrial shunting for heart failure.
CustomersInvestment
growth-positive
V-Wave Completes Financing of $98M from Syndicate of Leading Global Healthcare Investors
V-Wave Ltd., a cardiovascular device company, has successfully closed the remaining tranches of its Series C extension, raising a total of $98M. The funding will support the completion of the clinical trial for the Ventura Interatrial Shunt for the treatment of advanced heart failure and the submission of a PMA for Agency review. It will also fund the continued development of V-Waves product pipeline. The financing was led by Deerfield Management and included participation from various other investors. The Ventura Shunt is currently being evaluated in an international, multicenter RELIEVE-HF randomized trial. V-Waves technology has been designated as a Breakthrough device by the FDA. The company aims to address the unmet clinical and economic need for new therapies for heart failure.
Investment
growth-positive
V-Wave Completes Financing of Up to $98M from Syndicate of Leading Global Healthcare Investors
V-Wave Ltd., a cardiovascular device company, has closed a Series C extension of up to $98M. The financing will support the completion of clinical trials for their Ventura Interatrial Shunt for the treatment of advanced heart failure and obtaining FDA clearance. The shunt is being evaluated in the RELIEVE-HF trial and the RELIEVE-PAH trial. The financing was led by Deerfield Management and included participation from various other investors. The company aims to develop a disruptive technology that can modify the physiology of heart failure by reducing left atrial and pulmonary artery pressures. The Ventura shunt has received positive feedback from physicians in terms of ease of use and reliability. V-Wave is addressing the unmet clinical and economic need for simple and cost-effective therapies for heart failure.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $132.5M |
| Last funding | $98M |
| Stage | Acquired |
| Rounds | 4 |
| Investors | 12 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | vwavemedical.com |
Locations
Tarshish 5, Caesarea, Israel
29219 Canwood Street, Agoura Hills, CA, USA
Photos & Videos
2 item(s)
